Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from calcineurin inhibitor therapy to sirolimus in cardiac transplant recipients with renal dysfunction
2006-002420-41Phase 3Completed
- Sponsor
- Wyeth
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in post-orthotopic heart transplantation status, Renal Insufficiency (RI) and Cardiac Rejection (2 arms), sponsored by Wyeth. Primary endpoint: Change in creatinine clearance at 52 weeks. Started Aug 2006; status: completed.
02
Drugs
sirolimus
03
Conditions
post-orthotopic heart transplantation statusRenal Insufficiency (RI)Cardiac Rejection
Beyond the preview
Go deeper on 2006-002420-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002420-41.